Commercial feasibility of non-pathogenic Clostridium-Mediated Cancer Immunotherapy: leveraging the presence of tumour hypoxia & necrosis

Project Information

CL-IO

Grant agreement ID: 813200

DOI 10.3030/813200

Project closed

EC signature date 17 September 2018

Start date 1 October 2018

End date 31 March 2020

Funded under

• EXCELLENT SCIENCE - European Research Council (ERC)

Total cost € 150 802,50

EU contribution € 150 000,00

Coordinated by

UNIVERSITEIT MAASTRICHT
Netherlands

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .